Previous 10 | Next 10 |
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible th...
2023-11-09 14:56:37 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Ironwood ...
2023-11-09 10:39:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Offi...
2023-11-09 07:03:18 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals Q3 2023 Earnings Preview JMP starts Ironwood at market outperform, cites potent...
– LINZESS ® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year – – Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in shor...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $0.17 for Q3 2023
2023-11-08 13:37:25 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS JMP starts Ironwood at market outperform, cites potential of GLP-2 drug Seeking Alpha’s Quant Rat...
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...